IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 901-925 out of 1350.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

Public Release: 9-Feb-2015
Annals of Internal Medicine
News from Annals of Internal Medicine Feb. 10, 2015
Using Lung Imaging Reporting and Data System (Lung-RADS) criteria developed by the American College of Radiology to interpret low-dose CT lung screening results may reduce false positives compared to the National Lung Screening Trial, but the trade-off is reduced sensitivity, according to an article published in Annals of Internal Medicine.

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 9-Feb-2015
Nature Biotechnology
Computer model of blood development could speed up search for new leukaemia drugs
The first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments for leukaemia and lymphoma, say researchers at the University of Cambridge and Microsoft Research.
Medical Research Council, Biotechnology and Biological Sciences Research Council, Leukaemia and Lymphoma Research, Leukemia and Lymphoma Society, Microsoft Research, Wellcome Trust

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 9-Feb-2015
Cancer
Study identifies clinical signs suggestive of impending death in patients with advanced cancer
While the diagnosis of an impending death is always sad, it can be important for patients, families, and clinicians as they make decisions related to hospital discharge, hospice referral, and treatments.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 9-Feb-2015
JAMA Internal Medicine
HPV vaccination not linked to riskier sex
Receiving the HPV vaccine does not increase rates of sexually transmitted infections in adolescent females, suggesting that vaccinating girls is not likely to promote unsafe sexual activity.
National Institutes of Health, NIH/National Institute on Aging

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School

Public Release: 9-Feb-2015
Nature Genetics
UCSF-led study shows why some targeted cancer drugs lose effectiveness
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
NIH Director's New Innovator Award, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, National Lung Cancer Partnership, Sidney Kimmel Foundation for Cancer Research, Searle Scholars Program

Contact: Pete Farley
peter.farley@ucsf.edu
415-502-6397
University of California - San Francisco

Public Release: 6-Feb-2015
Technology
New method for minimally invasive tissue ablation surgery
The armamentarium of minimally invasive surgery is enriched with a new tissue ablation technique that employs the finding that reversible electroporation electric pulses, a mainstay tool of 21st century biotechnology, can substantially augment the effectiveness of electrolytic tissue ablation, a minimally invasive tissue ablation technique that has been used infrequently since its discovery at the beginning of the 19th century.

Contact: Philly Lim
mllim@wspc.com.sg
65-646-65775
World Scientific

Public Release: 6-Feb-2015
Journal of Clinical Investigation
We're all going to die; DNA strands on the end of our chromosomes hint when
BYU professor Jonathan Alder is currently studying the gene mutations that cause people to have unnaturally short telomeres. Recent research he coauthored with collaborators at Johns Hopkins University, published in the Journal of Clinical Investigation and Chest, finds those mutations are connected to both pulmonary fibrosis and emphysema.
National Institutes of Health

Contact: Todd Hollingshead
toddh@byu.edu
801-422-8373
Brigham Young University

Public Release: 5-Feb-2015
Angewandte Chemie International Edition
An 'ambulance' for the brain
Chemists at IRB Barcelona patent and present a shuttle capable of transporting molecules into the brain; this achievement could facilitate the treatment of diseases with no therapy available. Ninety-eight percent of drugs targeting the central nervous system are discarded.

Contact: Sònia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 5-Feb-2015
Genome Medicine
CNIO scientists link aggressiveness of chronic lymphocytic leukemia to genetic variability
The two subtypes of this kind of leukemia, mutated and non-mutated, show different levels of aggressiveness and are closely related to the genetic variability amongst individuals. If these results are confirmed by further research, a classifier based on gene expression variability could be designed for this kind of leukemia. The study has been published by the journal Genome Medicine.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 5-Feb-2015
Lancet Oncology
Two major studies strengthen case for prostate cancer drug before chemotherapy
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown.

Contact: Claire Hastings
chastings@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 5-Feb-2015
Preventive Medicine
Text messages a new tool in the fight to prevent skin cancer
Australians' love affair with mobile phones could save their life according to a joint QUT, Cancer Council Queensland and University of Queensland study using text messages to improve skin cancer prevention and promote sun protection.
Cancer Australia

Contact: Amanda Weaver
amanda.weaver@qut.edu.au
Queensland University of Technology

Public Release: 5-Feb-2015
Cell Stem Cell
Human stem cells repair damage caused by radiation therapy for brain cancer in rats
For patients with brain cancer, radiation is a potentially life-saving treatment, but it can also cause considerable and even permanent injury to the brain. Now, through preclinical experiments conducted in rats, researchers have developed a method to turn human stem cells into cells that are instructed to repair damage in the brain. As reported in Cell Stem Cell, rats treated with the human cells regained cognitive and motor functions that were lost after brain irradiation.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 5-Feb-2015
Science
Massively parallel sequencing technology for single-cell gene expression published
A new next-generation single-cell approach published in Science by scientists from Cellular Research, Inc. offers a massively parallel way to study gene expression.

Contact: Nicole Litchfield
nicole@bioscribe.com
415-793-6468
Bioscribe

Public Release: 5-Feb-2015
British Journal of Cancer
Overweight children may be at higher risk of esophageal cancer as adults
Overweight children may be at higher risk of esophageal (gullet) cancer when they grow up than their slimmer friends, according to research published this week in the British Journal of Cancer.
Intramural Program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, European Research Council, European Union's Seventh Framework Programme

Contact: Liz Smith
liz.smith@cancer.org.uk
020-346-98300
Cancer Research UK

Public Release: 5-Feb-2015
Blood
Analysis: High-cost blood cancer drugs deliver high value
Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. Researchers present this viewpoint, based upon a comprehensive analysis of published cost-effectiveness ratios, online today in Blood, the Journal of the American Society of Hematology.

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology

Public Release: 5-Feb-2015
Hepatology
Taking immunosuppressives, anti-cancer drugs may reactivate hepatitis B
Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, 'Reactivation of Hepatitis B,' and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. Reactivation of HBV can be fatal and the study authors suggest routine screening of HBV in all patients prior to the start of treatment with immunosuppressives or anti-cancer drugs.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 5-Feb-2015
Cell Reports
New study sheds light on cancer stem cell regulation
Researchers identify signaling molecules in intestinal stem cells that can lead to tumors if left unregulated. The findings suggest a new approach to targeting intestinal cancers.
National Institutes of Health, Department of Defense

Contact: Susan Gammon
sgammon@sanfordburnham.org
858-795-5012
Sanford-Burnham Medical Research Institute

Public Release: 5-Feb-2015
Science of the Total Environment
Reports from Columbia's Superfund program show many US wells tainted with arsenic
Arsenic is the biggest public-health problem for water in the United States -- yet we pay far less attention to it than we do to lesser problems. The Superfund Research Program, directed by Mailman School of Public Health professor Joseph Graziano, Ph.D., says private wells present continuing risks. Even low doses of arsenic may reduce IQ in children. There are also well-documented risks of cancer, heart disease, and reduced lung function.
National Institutes of Health

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health

Public Release: 5-Feb-2015
Journal of Neuropathology & Experimental Neurology
Cell signaling pathway goes awry in common pediatric brain tumor
A new study by Johns Hopkins researchers links a well-known cell communication pathway called Notch to one of the most common -- but overall still rare -- brain tumors found in children.
Knights Templar Eye Foundation, Childhood Brain Tumor Foundation, National Institutes of Health, Lauren's First and Goal, Pilocytic/Pilomyxoid Research Fund

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 5-Feb-2015
International Journal of Radiation Oncology • Biology • Physics
Patients with detectable PSA post-prostatectomy should receive more aggressive radiation therapy
Prostate cancer patients with detectable prostate specific antigen following radical prostatectomy should receive earlier, more aggressive radiation therapy treatment, according to a study published in the Feb. 1, 2015, issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 5-Feb-2015
Translational Research
Salicylates, a class of NSAIDs, stop vestibular schwannomas growth
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.
NIH/National Institute on Deafness and Other Communication Disorders, Berarelli Foundation, US Department of Defense

Contact: Mary Leach
Mary_Leach@meei.harvard.edu
Massachusetts Eye and Ear Infirmary

Public Release: 4-Feb-2015
European Journal of Cell Biology
Crucial role of breast cancer tumor suppressor revealed
A new study led by José Javier Bravo-Cordero, Spanish researcher at the Albert Einstein College of Medicine in New York, details how cells with low levels of the profilin 1 protein in breast tumors increase their capacity to metastasize and invade other tissues.

Contact: Sinc Agency
info@agenciasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology

Public Release: 4-Feb-2015
ACS Applied Materials & Interfaces
Tiny robotic 'hands' could improve cancer diagnostics, drug delivery
Many people imagine robots today as clunky, metal versions of humans, but scientists are forging new territory in the field of 'soft robotics.' One of the latest advances is a flexible, microscopic hand-like gripper. The development could help doctors perform remotely guided surgical procedures or perform biopsies. The materials also could someday deliver therapeutic drugs to hard-to-reach places. The report appears in the journal ACS Applied Materials & Interfaces.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 4-Feb-2015
Science Translational Medicine
Electricity delivers therapy to tumors in potentially new treatment, bioengineer says
A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients. Called iontophoresis, the technique delivers chemotherapy to select areas.

Contact: Eleanor Nelsen
enelsen@vt.edu
540-231-2761
Virginia Tech

Public Release: 4-Feb-2015
Proceedings of the National Academy of Sciences
An extra protein gives naked mole rats more power to stop cancer
A protein newly found in the naked mole rat may help explain its unique ability to ward off cancer. The protein is associated with a locus that is also found in humans and mice. It's the job of that locus to encode several cancer-fighting proteins. As professor of biology Vera Gorbunova explains, the locus found in naked mole rats encodes a total of four cancer-fighting proteins, while the human and mouse version encodes only three.
National Institutes of Health, Life Extension Foundation, Glenn Foundation for Medical Research, Ellison Medical Foundation

Contact: Peter Iglinski
peter.iglinski@rochester.edu
585-273-4726
University of Rochester

Showing releases 901-925 out of 1350.

<< < 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 > >>

  Search News Releases

     

 

EurekAlert!